GSK (NYSE:GSK) Stock Rating Upgraded by StockNews.com

GSK (NYSE:GSK) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.

A number of other research firms also recently commented on GSK. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Barclays raised GSK to a “hold” rating in a research report on Tuesday, August 27th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Down 2.2 %

NYSE GSK opened at $34.44 on Thursday. GSK has a 52 week low of $32.83 and a 52 week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The stock’s 50 day moving average price is $36.46 and its two-hundred day moving average price is $39.43. The stock has a market capitalization of $71.37 billion, a price-to-earnings ratio of 22.36, a PEG ratio of 1.33 and a beta of 0.64.

Insider Buying and Selling

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.00% of the stock is owned by insiders.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC increased its position in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares during the period. Primecap Management Co. CA lifted its holdings in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after buying an additional 342,365 shares in the last quarter. Provident Trust Co. boosted its position in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after acquiring an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC grew its stake in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after acquiring an additional 833,080 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.